ABCDx develops point-of-care diagnostic solutions utilizing proprietary blood-based biomarkers to detect brain injuries. Their technology enables rapid clinical validation, providing healthcare professionals with timely and accurate assessments to improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for diagnosing brain injuries often rely on subjective assessments and imaging techniques that may not be readily available or timely, especially in point-of-care settings. This can lead to delays in diagnosis and treatment, potentially worsening patient outcomes.
Solution
ABCDx is developing point-of-care diagnostic solutions for the rapid detection of brain injuries, utilizing proprietary blood-based biomarkers. Their Software as a Medical Device (SaMD) platform enables clinical validation and provides healthcare professionals with timely and accurate assessments. By leveraging a panel of novel brain biomarkers, the technology aims to improve the speed and accuracy of brain injury diagnosis, facilitating quicker intervention and improved patient management. The solution offers a data-driven approach to brain injury assessment, potentially reducing reliance on subjective evaluations.
Target Audience
The primary target audience includes healthcare professionals in emergency rooms, intensive care units, and sports medicine clinics who require rapid and accurate brain injury assessments.
Features
- Proprietary blood-based biomarkers for detecting various types of brain injuries
- Point-of-care testing for rapid results in critical situations
- SaMD platform for clinical validation and data analysis
- Integration with existing healthcare systems for seamless data transfer
- Biomarker discovery and validation pipeline for continuous improvement